Bristol‑Myers Squibb announced on November 12, 2025 that it is expanding its partnership with the Sarah Cannon Research Institute (SCRI) to accelerate the development of its oncology portfolio and broaden patient access to clinical trials. The expanded collaboration builds on SCRI’s Accelero model, a next‑generation clinical‑trial delivery platform that streamlines operations and shortens study‑startup timelines.
SCRI’s Accelero model is supported by a network of more than 200 community sites and over 1,300 physicians across 20 states, allowing trials to reach patients in diverse geographic and demographic settings. Early data from the partnership show a 45 % reduction in study‑startup timelines across eight Bristol‑Myers Squibb trials, outperforming non‑SCRI sites and indicating a significant operational advantage for the company’s oncology programs.
The collaboration is expected to benefit key Bristol‑Myers Squibb assets such as Opdivo and Breyanzi, as well as emerging CAR‑T and bispecific antibody programs. In the third quarter of 2025, the company reported revenue of $12.22 billion, a 3 % increase from the $12.02 billion reported in Q3 2024. Growth‑portfolio revenues rose 18 % to $6.9 billion, while legacy‑portfolio revenues fell 12 % to $5.4 billion, underscoring the company’s strategic shift toward newer therapies.
Management highlighted the partnership’s role in supporting this shift. Senior Vice President Mokash Sharma emphasized that the Accelero model “improves access to clinical research, especially for medically underserved populations, and accelerates overall patient enrollment.” The company also raised its full‑year 2025 revenue guidance to $47.5 billion–$48.0 billion and its non‑GAAP EPS guidance to $6.40–$6.60, reflecting confidence in the growth‑portfolio momentum and the operational efficiencies gained through the partnership.
Market reaction to the announcement was tempered by a mix of positive and negative signals. The company’s Q3 2025 earnings beat revenue estimates but missed EPS expectations by $0.02, a shortfall attributed to higher-than‑expected operating costs and a modest decline in legacy‑portfolio sales. Investors noted the revenue beat and guidance raise as positive tailwinds, while concerns about patent expirations, generic competition, and pipeline risks remained headwinds. The expanded collaboration is viewed as a strategic move to strengthen the company’s pipeline and mitigate some of these risks over the long term.
The partnership represents a concrete step toward Bristol‑Myers Squibb’s broader strategy of accelerating innovation, expanding patient access, and building a robust growth portfolio. By leveraging SCRI’s accelerated trial model, the company aims to shorten development timelines, improve enrollment, and ultimately bring new oncology therapies to patients more quickly.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.